Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 23 October 2018, 14:13 HKT/SGT
Share:
    

Source: Eisai
Eisai: Application Seeking Manufacturing and Marketing Approval in Japan Submitted for Parkinson's Disease Treatment Safinamide

TOKYO, Oct 23, 2018 - (JCN Newswire) - Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced that an application seeking manufacturing and marketing approval in Japan was submitted as of today by Meiji for the Parkinson's disease treatment ME2125 (safinamide mesylate, "safinamide").

This application is primarily based on a double-blind, placebo-controlled Phase II/III study to evaluate the efficacy and safety of safinamide as add-on therapy, as well as an open label Phase III study to evaluate the safety and efficacy of long-term administration of safinamide in Japanese patients with Parkinson's disease with wearing-off phenomenon(*) who are currently receiving levodopa.

Under the license agreement signed between Eisai and Meiji in March 2017, Eisai has the exclusive rights to market safinamide in Japan, as well as to develop and market safinamide in Asia(**). Meiji conducted clinical trials, and then submitted a manufacturing and marketing authorization application for the drug in Japan. Eisai will submit applications for manufacturing and marketing approval for the drug in Asia.

Through the development of safinamide, Eisai and Meiji will make further contributions to address the diversified needs of, and increase the benefits provided to, Parkinson's disease patients and their families.

(*) Wearing off phenomenon: As the disease progresses, levodopa's duration of effect ("on" time) decreases, and Parkinson's disease symptoms return before the next dose
(**) South Korea, Taiwan, Brunei, Cambodia, Laos, Malaysia, the Philippines, Indonesia, Thailand, Vietnam, Myanmar, Singapore, Hong Kong, Macao

About safinamide mesylate (generic name, development code: ME2125)

Safinamide is a selective monoamine oxidase B (MAO-B) inhibitor, which reduces the degradation of excreted dopamine, helping to maintain the density of dopamine in the brain. Additionally, safinamide blocks sodium ion channels and inhibits glutamate release, and as such, has potential as a new Parkinson's disease treatment which possesses both dopaminergic and non-dopaminergic mechanisms. Global clinical trials of safinamide in combination with levodopa for the treatment of mid- to late-stage Parkinson's disease showed extended "on" time and an improvement in motor function.(1),(2)

Safinamide was discovered and developed by Newron Pharmaceuticals S.p.A. In 2011, Newron entered into a licensing agreement with Meiji, granting Meiji exclusive rights to develop, manufacture and commercialize the drug in Japan and Asia. Safinamide is marketed under the name "Xadago" in 15 countries in Europe and the United States.

About the Phase II/III Clinical Study (ME2125-3)

Study ME2125-3 was a multicenter, double-blind, placebo-controlled, randomized, parallel group study to evaluate the efficacy and safety of two doses of safinamide (50 and 100 mg, once a day for 24 weeks) administered orally as add-on therapy in Japanese patients with Parkinson's disease with wearing-off phenomenon who are currently receiving levodopa. In this study, the primary endpoint was the change in mean daily "on" time from baseline to 24 weeks of the treatment phase, and verified the superiority of each dose of safinamide over placebo.

About the Phase III Clinical Study (ME2125-4)

Study ME2125-4 was an open-label, multicenter study to evaluate the long-term efficacy and safety of two doses of safinamide (50 and 100 mg, once a day for 52 weeks) administered orally as add-on therapy in Japanese patients with Parkinson's disease with wearing-off phenomenon who are currently receiving levodopa. In this study, in addition to evaluating the safety of long-term administration of safinamide, the study evaluated the change in mean daily "on" time from baseline to 52 weeks of the treatment phase as the primary efficacy endpoint.

About Parkinson's Disease

Parkinson's disease is a neurodegenerative disease which causes motor impairment, including shaking in the limbs, muscular rigidity and shuffling gait. It is caused by degeneration of the dopamine nervous system, which leads to a shortage of dopamine, a neurotransmitter in the brain.

According to Eisai's internal estimates, there are approximately 300,000 patients suffering from Parkinson's disease in Asia (excluding China and India). According to a survey by the Ministry of Health, Labour and Welfare, the number of patients suffering from Parkinson's disease in Japan numbered 163,000 in 2014.(3) The number of patients increasing due to the aging of the population.(4)

Levodopa is widely used to treat Parkinson's disease by replenishing the brain's supply of dopamine. However, as the disease progresses, levodopa's duration of effect ("on" time) decreases, and there are cases of Parkinson's disease symptoms returning before the next dose ("wearing-off" phenomenon). To prevent the "wearing-off" phenomenon, combination therapy with a drug that has a different mechanism of action to levodopa is administered.

About Meiji Seika Pharma Co., Ltd.

In order to protect and improve people's health and lives, Meiji Seika Pharma, as a "Speciality and Generic Pharmaceuticals Company," runs its pharmaceutical business in the two main fields, infectious disease and central nervous system disorders, as well as generic drugs. Meiji Seika Pharma strives to respond to diversified medical needs and contributes to the well-being of people worldwide.

(1) Borgohain R et al. Randomized Trial of Safinamide Add-On to Levodopa in Parkinson's Disease With Motor Fluctuations. Mov Disord. 2014 Feb;29(2):229-37
(2) Schapira AH et al. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017 Feb 1;74(2):216-224
(3) Patient Survey 2014 (Disease and Injury) by Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare
(4) Japan Intractable Diseases Information Center: http://www.nanbyou.or.jp/


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Meiji Seika Pharma Co., Ltd.
Public Relations 
Tel: +81-(0)3-3273-5614

Eisai Co., Ltd.
Public Relations Department 
TEL: +81-(0)3-3817-5120


Oct 23, 2018 14:13 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 14, 2018 12:30 HKT/SGT
Eisai Receives "IR Grand Prix Award"
Nov 12, 2018 11:51 HKT/SGT
Eisai Launches Lenvima (Lenvatinib) in China
Nov 9, 2018 08:08 HKT/SGT
Eisai: New Data from Investigational Study of Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
Nov 8, 2018 14:38 HKT/SGT
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Anti-Fractalkine Antibody E6011 for Treatment of Crohn's Disease Concluded, Research Activities Commence
Nov 8, 2018 08:43 HKT/SGT
Eisai Commences Full-Scale Operation of New Suzhou Plant in China
Oct 29, 2018 08:45 HKT/SGT
Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at CTAD
Oct 26, 2018 08:32 HKT/SGT
Eisai Presents New Data on Lemborexant for Treatment of Irregular Sleep-Wake Rhythm Disorder in Patients With Alzheimer's Disease
Oct 26, 2018 07:03 HKT/SGT
Eisai and Biogen Announce Presentation of Additional Data from Phase II Clinical Trial of BAN2401 in Early Alzheimer's Disease
Oct 25, 2018 08:05 HKT/SGT
Eisai to Present Latest Data on Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination and Exploratory Research
Oct 22, 2018 16:34 HKT/SGT
Eisai and MSD Japan Commence Collaboration on Commercialization Activities for LENVIMA (Lenvatinib) in Japan
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: